Clair is decoding women’s well-being.
What’s happening: The wearable maker secured $11.6M ahead of launching its continuous hormone monitor in November.
Wearable 2.0. Using 10 biosensors and 130+ proprietary biomarkers, Clair’s wrist-worn device tracks estrogen, progesterone, LSH, and FSH, supplying insights across women’s life stages from menstruation to menopause.
With 35% of women already wearing a tracker, Clair’s targeted approach has fueled a 25K+ person waitlist. Keeping an edge in the wearable market, Clair’s latest raise will fund continued research.
Fundamental. Beyond generic metrics, wearable companies are doubling down on women’s health, from Apple’s menopause-tracking feature to Oura’s custom AI model.
While others are gradually layering in life stages, Clair is positioning hormones as foundational health, providing enhanced data contextualization around underserved conditions spanning PMOS and perimenopause. Likewise, newcomers Peri and Braav are focusing on the metrics as they enter the crowded wearable market.
Punchline: Months ahead of launch, Clair’s raise and growing waitlist are proving that women’s health isn’t just an add-on feature, but the whole product.
